Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Placebo-controlled, Double-blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients.

NCT02195232 is registered in ClinicalTrials.gov with Jeffrey Zwicker, MD as lead sponsor.

NCT NCT02195232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02195232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Placebo-controlled, Double-blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients.
Lead sponsor
Jeffrey Zwicker, MD
Phase
Phase 2/3
Overall status
Completed
Start date
January 31, 2015
Completion date
October 22, 2019
Enrollment
64 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

thromboembolism of vein in non-small cell lung cancer, thromboembolism of vein in pancreatic cancer, thromboembolism of vein vte in colorectal cancer